Combined with the Faghihi 2021 study that directly compared 0.6 mm to 1.2 mm and found no significant difference, the evidence increasingly supports shorter needles
In addition, clinicians now have more flexibility when tailoring treatment plans
The topical route is the format with the strongest human clinical trial evidence for skin outcomes, from the landmark 1998 Abdulghani study that outperformed both vitamin C and tretinoin to the Finkley skin-thickness data
2, pp 500 [online] Available at: Larsson, S.C., Hakansson, N., and Wolk, A
Telehealth providers in the cash-pay GLP-1 market will pick up some patients who lose coverage, but many consumers wont be able to absorb the jump from an insurance copay (~$25) to paying at least a few hundred dollars out of pocket
And then this class of diabetes drugs, and sort of tellingly, it's these huge companies in diabetes, Eli Lilly and Novo Nordisk, which have worked in insulin for almost a century, that brought these drugs to the market for obesity
